Key Highlights
- BioNTech and Pfizer have secured a non-exclusive U.S. license from CureVac to manufacture, use, import, and sell mRNA-based COVID-19 and influenza products, resolving patent litigation and enabling uninterrupted commercial operations.
- Upon closing BioNTech’s planned acquisition of CureVac, the license will expand worldwide, providing BioNTech broad freedom to operate globally while releasing both parties from prior infringement claims.
- The settlement includes $740 million in payments and ongoing royalties to CureVac and GSK, allowing BioNTech to focus on advancing its mRNA pipeline including cancer immunotherapies and infectious disease vaccines.
Resolving Patent Litigation and Securing Licenses
BioNTech SE and Pfizer reached agreements with CureVac N.V. and GlaxoSmithKline (GSK) to settle ongoing U.S. and international patent disputes related to mRNA technology used in COVID-19 vaccines. The agreement dismisses CureVac’s U.S. infringement lawsuit and grants BioNTech and Pfizer a non-exclusive license to produce and commercialize mRNA COVID-19 and influenza products in the U.S., with an expanded global license following completion of the BioNTech acquisition of CureVac. This effectively removes legal uncertainties, securing BioNTech’s intellectual property position crucial for ongoing product supply and market expansion.
Financial Terms and Royalty Agreements
As part of the settlement, BioNTech will pay a total of $740 million to CureVac and GSK combined, including upfront payments and royalties on U.S. sales of licensed COVID-19 and influenza products commencing January 1, 2025. Post-acquisition, additional payments including $130 million to GSK and 1% royalties on global sales will apply. Pfizer has agreed to reimburse BioNTech for $80 million plus half of claimed royalties on sales of mRNA-based COVID-19 products, reflecting shared commercial interests. These financial arrangements provide compensation for CureVac’s longstanding mRNA intellectual property claims while enabling BioNTech and Pfizer to streamline commercialization.
Strategic Importance for BioNTech’s Growth and Pipeline
This settlement and licensing arrangement clears a key strategic hurdle for BioNTech, allowing it to integrate CureVac’s complementary mRNA technology platforms and continue expanding its leadership in mRNA therapeutics. BioNTech’s diversified oncology, infectious disease, and vaccine pipelines benefit from this intellectual property freedom, accelerating R&D and commercialization efforts. The agreement supports BioNTech’s mission to develop breakthrough mRNA medicines beyond COVID-19, including highly personalized cancer immunotherapies and next-generation infectious disease vaccines.
Global mRNA Industry Positioning
By resolving disputes and bringing CureVac under its corporate umbrella, BioNTech consolidates its standing as a global mRNA innovator with expanded manufacturing and IP capabilities. The settlement reflects a maturation of the mRNA vaccine market, moving toward cooperation and innovation over patent conflicts. BioNTech’s strengthened licensing rights and pipeline synergy position it favorably amidst increasing competition and evolving regulatory landscapes in biotech and pharmaceuticals.
This landmark settlement marks a critical turning point for BioNTech in safeguarding its market presence and driving the next generation of mRNA-enabled health solutions worldwide.
For more detailed information, please visit BioNTech’s official news release and company website.
By